MedTrace Logo

18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

NCT04365660 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-11-14

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").

Conditions

Interventions

DRUG

18-F FTC 146

Radiotracer, 10 mCi at pre- and post- chemotherapy, intravenous administration

Sponsors & Collaborators

  • Davidzon, Guido, M.D.

    lead OTHER

Principal Investigators

  • Kristen N Ganjoo · Stanford Universiy

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-28
Primary Completion
2021-05-28
Completion
2021-07-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04365660 on ClinicalTrials.gov